GT BIOPHARMA, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
GT BIOPHARMA, INC. (GTBP) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $4.00 thousand as of 2014-09-30, per its 10-Q filed 2015-01-08.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2015-01-08
- 2014-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.00K.
- 2014-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.00K.
- 2014-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.00K.
- 2013-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One | Finite-Lived Intangible Asset, Expected Amortization, Year One as first filed |
|---|---|---|
| 2014-09-30 | $4.00K 10-Q · filed 2015-01-08 | |
| 2014-06-30 | $4.00K 10-Q · filed 2015-01-08 | |
| 2014-03-31 | $4.00K 10-Q · filed 2015-01-08 | |
| 2013-12-31 | $4.00K 10-K · filed 2015-01-08 | |
| 2013-09-30 | $4.00K 10-Q · filed 2014-12-17 | |
| 2012-12-31 | $4.00K 10-Q · filed 2014-12-12 | |
| 2011-12-31 | $4.00K 10-K · filed 2014-11-18 | $12.00K 10-Q/A · filed 2012-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |